Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to 0.4%.

  • Beam Therapeutics' Return on Capital Employed fell 2300.0% to 0.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4%, marking a year-over-year decrease of 2300.0%. This contributed to the annual value of 0.38% for FY2024, which is 2300.0% down from last year.
  • As of Q3 2025, Beam Therapeutics' Return on Capital Employed stood at 0.4%, which was down 2300.0% from 0.36% recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Return on Capital Employed registered a high of 0.15% during Q1 2024, and its lowest value of 0.65% during Q1 2021.
  • Over the past 5 years, Beam Therapeutics' median Return on Capital Employed value was 0.34% (recorded in 2023), while the average stood at 0.32%.
  • As far as peak fluctuations go, Beam Therapeutics' Return on Capital Employed skyrocketed by 4300bps in 2022, and later crashed by -2800bps in 2024.
  • Beam Therapeutics' Return on Capital Employed (Quarter) stood at 0.36% in 2021, then increased by 15bps to 0.3% in 2022, then skyrocketed by 50bps to 0.15% in 2023, then crashed by -188bps to 0.43% in 2024, then rose by 8bps to 0.4% in 2025.
  • Its Return on Capital Employed was 0.4% in Q3 2025, compared to 0.36% in Q2 2025 and 0.38% in Q1 2025.